Organization | Danish Breast Cancer Cooperative Group

Danish Breast Cancer Cooperative Group Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Copenhagen Denmark (1976)

Organization Overview

First Clinical Trial

1998

NCT00004205

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Danish Breast Cancer Cooperative Group

Active Ingredients

Drugs in Phase 3 Trials (11)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

docetaxel (taxotere) (2 trials)

epirubicin (ellence) (3 trials)

fluorouracil (efudex) (1 trial)

letrozole (femara) (3 trials)

paclitaxel (taxol) (1 trial)

tamoxifen (nolvadex) (2 trials)

trastuzumab (herceptin) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (1)

2x-121 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 8
# of Trial APIs: 12